Physician profile
Devorah E Ben-Zeev
NPI 1033160692
$2,387.21
in general payments reported to CMS, 2019-2025
25 companies · $680 in 2025
The $680 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $365 · 2020: $169 · 2022: $121 · 2023: $453 · 2024: $600 · 2025: $680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,715 · Education: $17.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,715.24 |
| Education | $17.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $314.14 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $237.50 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $225.43 | 2019-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $194.24 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $187.75 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.41 | 2019-2025 | Jardiance |
| Amgen INC. | $146.18 | 2022-2024 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $126.45 | 2023-2025 | |
| Astellas Pharma US INC | $117.59 | 2019-2025 | Veozah |
| Exact Sciences Corporation | $101.76 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $86.55 | 2019-2024 | Belsomra, Capvaxive, Gardasil 9 |
| Abbvie INC. | $69.19 | 2025 | |
| Amarin Pharma, INC. | $57.66 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $47.68 | 2020-2023 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.03 | 2019-2024 | Xifaxan |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $43.96 | 2023-2025 | Heplisav-B |
| Janssen Pharmaceuticals, INC | $36.09 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $30.21 | 2025 | |
| Insmed, INC. | $29.68 | 2025 | Arikayce |
| Agios Pharmaceuticals, INC. | $29.34 | 2025 | Pyrukynd |
| Lundbeck LLC | $20.61 | 2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $20.30 | 2025 | Rexulti |
| Madrigal Pharmaceuticals | $20.18 | 2025 | Rezdiffra |
| Bayer Healthcare Pharmaceuticals INC. | $19.99 | 2025 | |
| Inspire Medical Systems, INC. | $18.29 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devorah Ben-Zeev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.